AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00142415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111-In-DOTA-cG250
Description: On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.
Study NCT00142415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177-Lu-DOTA-cG250
Description: On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m\^2 in the initial cohort.
Study NCT00785993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitrification of oocytes for IVF treatment
Study NCT00785993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocolary IVF treatment with fresh donor oocytes
Study NCT01896323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223
Description: CC-223 20 mg tablets
Study NCT01896323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: Ketoconazole 400 mg tablets
Study NCT01360710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine
Description: 0.2mg/day for 2 weeks, 0.4mg/day for 6 months
Study NCT01360710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: 75 mg/day for 2 weeks and then 150 mg/day for 24 weeks.
Study NCT04580082 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness lessons
Description: 14 lessons on mindfulness, each lasting approximately 20 minutes.
Study NCT04580082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness lessons
Description: 14 lessons on mindfulness, each lasting approximately 20 minutes.
Study NCT02162797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Description: Intervention group A: Patients who will orally receive zinc for 3 months.
Study NCT00139529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Telephone Counseling
Description: Participants will receive up to 5 phone calls.
Study NCT00139529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Educational intervention will be completed during pregnancy.
Study NCT00139529 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Educational intervention will be completed during pregnancy.
Study NCT00537277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart
Description: Treat-to-target dose titration scheme (dose individually adjusted), injected s.c. (under the skin)
Study NCT02645890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-397
Description: Arm A:Tamsulosin/ Tadalafil Fixed dose combination
Study NCT02645890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD+TM
Description: Arm B: Tamsulosin/ Tadalafil Coadministration
Study NCT02372461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is an non inferiority trial, the intervention is a placebo
Study NCT02372461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin Liquid
Study NCT00382356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: once daily dosing of 0.5mg Dutasteride for 12 months
Study NCT02771964 — intervention group
Intervention type: OTHER
Intervention: Quality of life survey
Description: All enrolled patients complete a survey of baseline health during their visit to the preoperative assessment clinic and then complete a follow-up survey approximately 30 days after surgery.~The intervention for this study is to compare self-reported quality of life (How would you rate your quality of life now? (better/same/worse)) to the quantitative change in their VR-12 quality of life scores between the baseline survey and 30-day follow-up survey.
Study NCT02820662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RETCAM
Study NCT02820662 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Study NCT01005381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Small Particle Size Calcium Carbonate Supplement
Description: Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.
Study NCT01005381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Small Particle Size Calcium Carbonate Supplement
Description: Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.
Study NCT01005381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Large Particle Size Calcium Carbonate Supplement
Description: Large Particle Size Calcium Carbonate Supplement - tablet, 325 mg/tablet. Given twice daily.
Study NCT01005381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D - capsule, cholecalciferol, 1000 IU/tablet. Given once daily.
Study NCT01005381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Placebo
Description: Placebo tablets identical to the large and small particle size calcium carbonate tablets.~Given twice daily.
Study NCT04224467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous ICG and Real-Time Near-infrared Imaging
Description: Patients will be intravenously injected ICG (Yichuang Pharmaceutical Limited Liability Company, Dandong, China) at a dose of 2-5 mg per kg of body weight before surgery or 0.25-0.5 mg per kg of body weight during surgery. Then real-time near-infrared imaging will be conducted during surgery.
Study NCT03998631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide and Saline Flush
Description: The TEVAR or TAVI device will be flushed with approximately 1.2L of medical grade carbon dioxide using a 60mL syringe and connecting tubing. The reservoir will then be flushed with at least 60mL of standard saline prior to deployment to minimize bubbles in the saline.
Study NCT03998631 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Saline Flush
Description: Standard of care flushing of the TEVAR or TAVI device with normal saline.
Study NCT01770964 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin
Study NCT02162797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo supplementation
Description: Intervention Group B: Patients who will orally receive a placebo for 3 months.
Study NCT00002768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 10 microgram/kg body wt subcutaneously daily beginning on d 14 and con't until peripheral blood collection is completed
Study NCT00002768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: 1 mg/kg PO q 6 hrs for 16 doses on days -7 thru -4.
Study NCT00002768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 2000 mg/ sq meter IV over 2 hours q 12 hrs x 8 doses on days 1-4
Study NCT00002768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 40 mg/kg (total dose) IV cont infusion over 96 hrs on days 1-4 of consolidation therapy and 60 mg/kg IV over 4 hrs on day -3 of transplant
Study NCT00002768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation
Study NCT01770964 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Study NCT01770964 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Training Type A
Study NCT00002768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Infusion on Day 0
Study NCT04542161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC 900mg/day
Description: self administer NAC 900mg/day caplets for a four week period
Study NCT01770964 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Training Type B
Study NCT01836120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed plus Docetaxel
Description: Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d~1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)
Study NCT01836120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)
Study NCT01697579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Administered intravenously (IV) as a single dose
Study NCT01697579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fosaprepitant Placebo
Description: Administered IV as a single dose
Study NCT01697579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Administered IV according to local labeling and/or local standard of care
Study NCT01697579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: Administered IV according to local labeling and/or local standard of care
Study NCT01697579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptamine 3 antagonist
Description: Administered IV according to local labeling and/or local standard of care
Study NCT01654887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound
Description: Six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
Study NCT01654887 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chest X-Ray
Description: Posterior-Anterior and lateral views of the chest via chest radiography followed by a lung ultrasound which is comprised of six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
Study NCT02632318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light
Description: 30 minutes of dawn simulation
Study NCT04587713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet A]
Description: TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation
Study NCT04542161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC 3600mg/day
Description: self administer NAC 3600mg/day caplets for a four week period
Study NCT04542161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NAC 0mg/day (Placebo)
Description: self administer NAC 0mg/day (placebo) caplets for a four week period
Study NCT04587713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet B]
Description: TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation
Study NCT03684668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Description: The intervention will be carried out every 24 hours with four participants in four computers and 3D lenses available in the computer labs of the University.
Study NCT03913923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-217
Description: Combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies, 1mg/kg and 3 mg/mg, respectively, given Q3W as IV infusion for first 4 blinded infusions
Study NCT03913923 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCD-100
Description: Anti-PD-1 monoclonal antibody, 3 mg/kg, given Q3W as IV infusion for first 4 blinded infusions, after - 1 mg/kg, given Q2W as IV infusion
Study NCT03913923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Anti-PD-1 monoclonal antibody, 3 mg/kg, given Q3W as IV infusion for first 4 blinded infusions, after - 1 mg/kg, given Q2W as IV infusion
Study NCT03185078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy
Description: Extracorporeal shock wave therapy (ESWT) is a treatment method for the application of single-pulse acoustic pressure waves generated by sudden changes in pressure by creating shock waves with piezoelectric, electrohydraulic and electromagnetic systems. It has been reported that ESWT treatment is effective in the treatment of pain with hyperstimulation analgesia by inhibiting afferent pain receptors, and also improve angiogenesis and restore and reorganize the musculoskeletal system
Study NCT03913923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03913923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02794415 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Community-based exercise
Description: Intervention Phase (6 months): The HIV Community-Based Exercise (CBE) intervention is a 6-month exercise program at the Central Toronto YMCA. Participants will meet the fitness instructor to establish an individualized exercise program that will include a combination of aerobic, resistive, neuromotor and flexibility training. Participants will attend exercise sessions for \~1.5 hour, 3 times per week for 24 weeks. Sessions will be supervised weekly by a fitness instructor.~Post-Intervention Phase (8 months): At the end of the 24 week intervention, participants will be encouraged to continue to engage in unsupervised exercise 3 times per week. As per usual practice at the YMCA, a fitness instructor will be available to monitor participants monthly.
Study NCT02741323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR \< 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).~Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability.
Study NCT02741323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR \< 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).~Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability.
Study NCT01806623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Single oral dose of 150mg Fluconazole
Study NCT01240187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perampanel
Description: Single dose of 6 tablets 2 mg orally
Study NCT01240187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perampanel
Description: Single dose of 1 tablet 12 mg orally
Study NCT02521987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 8mm port
Description: Participate in this arm will have their procedure performed with an 8mm laparoscopic port.
Study NCT02521987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 12mm port
Description: Participate in this arm will have their procedure performed with a 12mm laparoscopic port.
Study NCT03185078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo ESWT
Description: In the placebo application, rESWT device was switched on but without pressing the pedal during the same session period. The applicator was positioned to be the same as the other groups.
Study NCT03185078 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo ESWT
Description: In the placebo application, rESWT device was switched on but without pressing the pedal during the same session period. The applicator was positioned to be the same as the other groups.
Study NCT01355965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous T cells
Study NCT03057418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aurixim
Description: Administration will be performed once a week during 4-week induction period, and then once per 12 weeks during supporting period, if necessary. Total maximum duration of the investigational therapy - 1 year, during which patients will receive up to 8 infusions of Aurixim.
Study NCT00390689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.125 mg tablet
Study NCT00390689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg tablet
Study NCT01396564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 850 mg of Metformin daily, increased to 1700 mg after 12 weeks, for the duration of the trial.
Study NCT01396564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 15 mg of pioglitazone daily, increased to 60 mg after 12 weeks.
Study NCT00092001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
Study NCT01808326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorambucil, tablets
Description: 2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
Study NCT03045835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BASKA mask
Description: Baska mask will be inserted during induction of anaesthesia and once patient is in an adequate anaesthetic depth
Study NCT00350545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2;IV infusion once weekly for four doses (days 1,8,15,22); option for second 4-week course at week 9
Study NCT03045835 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation will be carried out during induction of anaesthesia and once patient is in an adequate anaesthetic depth
Study NCT00350545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 1 mg/kg; po per day with taper
Study NCT00350545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: trough 200-300 or lower; po
Study NCT00350545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: trough 5-10 or lower; po
Study NCT01493622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline
Description: variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
Study NCT01493622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
Study NCT03143023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arginine toothpaste
Description: acid neutralizer toothpaste
Study NCT03143023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoride toothpaste
Description: bactericidal toothpaste
Study NCT03966066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythromycin
Description: 3-5mg/kg.d orally for 6 months
Study NCT00464685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria.
Study NCT00464685 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Initial sham injection with up to 1 additional treatment based on re-treatment criteria.
Study NCT00464685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Photocoagulation
Description: Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
Study NCT00464685 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laser Photocoagulation
Description: Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
Study NCT01587313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate / hydralazine capsules
Description: Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid